Ana Lucas Quintero
Research Subjects
Ana Lucas Quintero has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abigail De Avila
CEVAXIN, Panama, Panama, Panama
2 shared publications - Cynthia Gadea
Faculty of Medicine, University of Panama, Panama City, Panama, Panama
2 shared publications - Emmanuel Guillén
Faculty of Medicine, University of Panama, Panama City, Panama, Panama
2 shared publications - Isaac Fernández Camargo
Faculty of Medicine, University of Panama, Panama City, Panama, Panama
2 shared publications - Jaime Ricardo Sevillano Giraldez
Department of Population Intelligence, Endpoints Research Sites Network, Panama, Panama, Panama
2 shared publications - Luis Flores
Faculty of Medicine, University of Panama, Panama City, Panama, Panama
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by MDPI AG in Preprints.org
Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025
Background/Objectives. Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infection in infants. Panama introduced the bivalent prefusion F vaccine (RSVpreF) for administration between 32.0 and 36.6 weeks of gestation in July 2025. In this tropical setting, respiratory viruses are detected throughout the year, with RSV activity increasing during the rainy season. We characterized self-reported maternal and neonatal events and outcomes to generate early post-introduction real-world safety evidence from Central America. Methods. This retrospective descriptive observational study included women aged 18 years or older vaccinated with RSVpreF between 32.0 and 36.6 weeks of gestation from July through December 2025 and recruited from January through July 2026. Structured telephone, virtual, or in-person interviews were used. We calculated absolute and relative frequencies and 95% Wilson confidence intervals (CIs). Results. Of 225 questionnaires obtained, 200 were eligible for analysis. Mean maternal age was 28.1 years (SD 6.4). At least one reaction was reported by 55.5% of participants, mainly local; injection-site pain was most frequent (48.0%). At least one obstetric condition was reported by 17.5%, including hypertensive disorders of pregnancy (12.0%). Preterm birth occurred in 2.0% and low birth weight in 2.5%. No fetal or neonatal deaths, thrombocytopenia, paralysis, facial paralysis, or Guillain–Barré syndrome were reported. Jaundice was the most frequent neonatal morbidity (20.0%). Conclusions. In this cohort, self-reported reactogenicity was mainly local, and no unexpected cluster of events was apparent. Participant selection, retrospective self-report, absence of an unvaccinated comparator, and sample size limit risk estimation and detection of uncommon events. The findings provide early active-pharmacovigilance evidence from Central America and support continued surveillance with clinically verified maternal and neonatal outcomes.
- 17 August 2026
- Published by MDPI AG in Preprints.org
Open AccessSafety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025
Background/Objectives. Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infection in infants. Panama introduced the bivalent prefusion F vaccine (RSVpreF) for administration between 32.0 and 36.6 weeks of gestation in July 2025. In this tropical setting, respiratory viruses are detected throughout the year, with RSV activity increasing during the rainy season. We characterized self-reported maternal and neonatal events and outcomes to generate early post-introduction real-world safety evidence from Central America. Methods. This retrospective descriptive observational study included women aged 18 years or older vaccinated with RSVpreF between 32.0 and 36.6 weeks of gestation from July through December 2025 and recruited from January through July 2026. Structured telephone, virtual, or in-person interviews were used. We calculated absolute and relative frequencies and 95% Wilson confidence intervals (CIs). Results. Of 225 questionnaires obtained, 200 were eligible for analysis. Mean maternal age was 28.1 years (SD 6.4). At least one reaction was reported by 55.5% of participants, mainly local; injection-site pain was most frequent (48.0%). At least one obstetric condition was reported by 17.5%, including hypertensive disorders of pregnancy (12.0%). Preterm birth occurred in 2.0% and low birth weight in 2.5%. No fetal or neonatal deaths, thrombocytopenia, paralysis, facial paralysis, or Guillain–Barré syndrome were reported. Jaundice was the most frequent neonatal morbidity (20.0%). Conclusions. In this cohort, self-reported reactogenicity was mainly local, and no unexpected cluster of events was apparent. Participant selection, retrospective self-report, absence of an unvaccinated comparator, and sample size limit risk estimation and detection of uncommon events. The findings provide early active-pharmacovigilance evidence from Central America and support continued surveillance with clinically verified maternal and neonatal outcomes.
- Open Access
- 14 August 2026
- Published by MDPI AG in Preprints.org
Maternal Vaccination Perceptions, Attitudes and Practices Among Urban Women Receiving Antenatal Care in Panama City: A Cross-Sectional Study
Background/Objectives: Maternal immunization is a public health priority within Panama's Expanded Programme on Immunization (EPI), yet coverage among pregnant women remains below target and little local evidence is available on perceptions and practices among women engaged in antenatal care. We aimed to describe vaccination-related perceptions, attitudes and practices in an urban, predominantly private-care sample and to explore factors associated with acceptance. Methods: We conducted a cross-sectional study in 204 pregnant women aged ≥18 years, recruited by convenience sampling and surveyed with an anonymous, self-administered questionnaire. Vaccine acceptance was defined as having received or intending to receive at least one recommended vaccine during the current pregnancy. Participant characteristics were summarized descriptively; bivariate analyses and multivariable Poisson regression with robust variance estimated adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs). Results: Acceptance was 93.1% (190/204). Most participants had higher education (88.2%) and private antenatal care (77.9%); all reported antenatal care. Healthcare professionals were the main information source (92.6%) and most trusted source (98.0%). A vaccination recommendation was reported by 84.3% of participants; 96.5% of reported recommendations came from healthcare professionals. Influenza was most frequently received (56.9%), RSV most frequently planned (51.5%), and COVID-19 most frequently refused (47.1%). Recommendation was associated with acceptance (adjusted PR 1.22; 95% CI 1.02–1.45; p = 0.029), but may reflect broader access to high-quality care. Conclusions: In this selected urban sample, acceptance was high among women engaged in antenatal care. The findings cannot characterize national acceptance; improving coverage likely requires equitable access to antenatal care, evidence-based counseling, recommendations, and vaccination opportunities.
- 14 August 2026
- Published by MDPI AG in Preprints.org
Open AccessMaternal Vaccination Perceptions, Attitudes and Practices Among Urban Women Receiving Antenatal Care in Panama City: A Cross-Sectional Study
Background/Objectives: Maternal immunization is a public health priority within Panama's Expanded Programme on Immunization (EPI), yet coverage among pregnant women remains below target and little local evidence is available on perceptions and practices among women engaged in antenatal care. We aimed to describe vaccination-related perceptions, attitudes and practices in an urban, predominantly private-care sample and to explore factors associated with acceptance. Methods: We conducted a cross-sectional study in 204 pregnant women aged ≥18 years, recruited by convenience sampling and surveyed with an anonymous, self-administered questionnaire. Vaccine acceptance was defined as having received or intending to receive at least one recommended vaccine during the current pregnancy. Participant characteristics were summarized descriptively; bivariate analyses and multivariable Poisson regression with robust variance estimated adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs). Results: Acceptance was 93.1% (190/204). Most participants had higher education (88.2%) and private antenatal care (77.9%); all reported antenatal care. Healthcare professionals were the main information source (92.6%) and most trusted source (98.0%). A vaccination recommendation was reported by 84.3% of participants; 96.5% of reported recommendations came from healthcare professionals. Influenza was most frequently received (56.9%), RSV most frequently planned (51.5%), and COVID-19 most frequently refused (47.1%). Recommendation was associated with acceptance (adjusted PR 1.22; 95% CI 1.02–1.45; p = 0.029), but may reflect broader access to high-quality care. Conclusions: In this selected urban sample, acceptance was high among women engaged in antenatal care. The findings cannot characterize national acceptance; improving coverage likely requires equitable access to antenatal care, evidence-based counseling, recommendations, and vaccination opportunities.
- Open Access
- 31 December 2025
- Published by Infomedic International in Revista Pediátrica de Panamá
- p. 129-137
Evolución del Programa Ampliado de Inmunización (PAI) en Panamá: avances, desafíos y perspectivas futuras
Introducción: El Programa Ampliado de Inmunización (PAI) ha sido una de las estrategias más exitosas de salud pública a nivel global y regional, logrando reducir significativamente la morbilidad y mortalidad por enfermedades. Métodos: Se realizó una reseña histórica de la evolución del PAI en Panamá, desde 1978 hasta 2025. Se revisaron documentos oficiales del Ministerio de Salud, informes técnicos, publicaciones científicas y normativa vigente. El análisis se organizó en cuatro dimensiones: implementación inicial, expansión del esquema, barreras y desafíos, y marcos normativos. Resultados: Panamá ha introducido 24 vacunas y 5 inmunoglobulinas en su esquema nacional. Entre los hitos destacan la universalización de hepatitis B, la incorporación de rotavirus, neumococo, varicela, influenza, virus de papiloma humano y COVID-19, así como la reciente inclusión de la vacuna contra virus sincitial respiratorio (VRS). Las coberturas infantiles se han mantenido sobre el 90%, contribuyendo a una reducción de la morbilidad y mortalidad y posicionando a Panamá entre los programas de mejor desempeño en la región. El país logró la interrupción de la transmisión endémica de poliomielitis y sarampión, además de la eliminación de rubéola y síndrome de rubéola congénita. Los principales desafíos incluyen oportunidades perdidas de vacunación, mayor independencia de la Comisión Nacional de Prácticas de Inmunizaciones (CONAPI), capacitación del personal y acceso a datos de vigilancia. Conclusiones: El PAI en Panamá constituye un modelo de equidad y acceso universal. Su sostenibilidad dependerá de la innovación tecnológica, el fortalecimiento de la gobernanza técnica y la colaboración multisectorial para enfrentar retos emergentes.
- 31 December 2025
- Published by Infomedic International in Revista Pediátrica de Panamá
- p. 129-137
Open AccessEvolución del Programa Ampliado de Inmunización (PAI) en Panamá: avances, desafíos y perspectivas futuras
Introducción: El Programa Ampliado de Inmunización (PAI) ha sido una de las estrategias más exitosas de salud pública a nivel global y regional, logrando reducir significativamente la morbilidad y mortalidad por enfermedades. Métodos: Se realizó una reseña histórica de la evolución del PAI en Panamá, desde 1978 hasta 2025. Se revisaron documentos oficiales del Ministerio de Salud, informes técnicos, publicaciones científicas y normativa vigente. El análisis se organizó en cuatro dimensiones: implementación inicial, expansión del esquema, barreras y desafíos, y marcos normativos. Resultados: Panamá ha introducido 24 vacunas y 5 inmunoglobulinas en su esquema nacional. Entre los hitos destacan la universalización de hepatitis B, la incorporación de rotavirus, neumococo, varicela, influenza, virus de papiloma humano y COVID-19, así como la reciente inclusión de la vacuna contra virus sincitial respiratorio (VRS). Las coberturas infantiles se han mantenido sobre el 90%, contribuyendo a una reducción de la morbilidad y mortalidad y posicionando a Panamá entre los programas de mejor desempeño en la región. El país logró la interrupción de la transmisión endémica de poliomielitis y sarampión, además de la eliminación de rubéola y síndrome de rubéola congénita. Los principales desafíos incluyen oportunidades perdidas de vacunación, mayor independencia de la Comisión Nacional de Prácticas de Inmunizaciones (CONAPI), capacitación del personal y acceso a datos de vigilancia. Conclusiones: El PAI en Panamá constituye un modelo de equidad y acceso universal. Su sostenibilidad dependerá de la innovación tecnológica, el fortalecimiento de la gobernanza técnica y la colaboración multisectorial para enfrentar retos emergentes.